William John Sibold - 04 Mar 2026 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Reporting relationship: President and CEO, Director
Issuer ticker: MDGL
Reported as of: 04 Mar 2026
Net transaction value: -$718,316
SEC form: 4
Accepted by SEC: 06 Mar 2026, 18:49:18 UTC
Prior SEC filing: 26 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Mardi Dier, as Attorney-in-Fact

Key filing fact

William John Sibold filed Form 4 for MADRIGAL PHARMACEUTICALS, INC. (MDGL) on 06 Mar 2026.

Key facts

This page summarizes William John Sibold's Form 4 filing for MADRIGAL PHARMACEUTICALS, INC. (MDGL).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Mar 2026, 18:49.

Change

Previous filing in this sequence was filed on 26 Jan 2026.
Current net transaction value: -$718,316.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001518611 Primary reporting owner

Sibold William John

Relationship: President and CEO, Director
Address: C/O MADRIGAL PHARMACEUTICALS, INC., 200 BARR HARBOR DRIVE, SUITE 200, WEST CONSHOHOCKEN
Signature: /s/ Mardi Dier, as Attorney-in-Fact
Signature date: 06 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MDGL transaction

Common Stock

Award

Transaction value
Shares: +14,995
Change %: +10%
Price: $0.000000^*
Shares after: 163,492
Date: 04 Mar 2026
Ownership: Direct
Footnotes: F1

MDGL transaction

Common Stock

Sale

Transaction value: $718,316
Shares: -1,663
Change %: -1%
Price: $431.94
Shares after: 161,829
Date: 06 Mar 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MDGL transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +18,743
Change %
Price: $0.000000^*
Shares after: 18,743
Date: 04 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 18,743
Exercise price: $434.80
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030, provided the Reporting Person continues in service with the Issuer on each such date.

Footnote F2

This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.

Footnote F3

The option vests as to 25% of the shares on the first anniversary of the date of grant (March 4, 2027) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.